You Liting, Zhou Juan, Xin Zhaodan, Hauck J Spencer, Na Feifei, Tang Jie, Zhou Xiaohan, Lei Zichen, Ying Binwu
Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Department of Pathology, Duke University School of Medicine, Durham, NC 27710, USA.
Precis Clin Med. 2022 Feb 3;5(1):pbac005. doi: 10.1093/pcmedi/pbac005. eCollection 2022 Mar.
Microbiome research has extended into the cancer area in the past decades. Microbes can affect oncogenesis, progression, and treatment response through various mechanisms, including direct regulation and indirect impacts. Microbiota-associated detection methods and agents have been developed to facilitate cancer diagnosis and therapy. Additionally, the cancer microbiome has recently been redefined. The identification of intra-tumoral microbes and cancer-related circulating microbial DNA (cmDNA) has promoted novel research in the cancer-microbiome area. In this review, we define the human system of commensal microbes and the cancer microbiome from a brand-new perspective and emphasize the potential value of cmDNA as a promising biomarker in cancer liquid biopsy. We outline all existing studies on the relationship between cmDNA and cancer and the outlook for potential preclinical and clinical applications of cmDNA in cancer precision medicine, as well as critical problems to be overcome in this burgeoning field.
在过去几十年中,微生物组研究已扩展到癌症领域。微生物可通过多种机制影响肿瘤发生、进展和治疗反应,包括直接调节和间接影响。已经开发出与微生物群相关的检测方法和试剂,以促进癌症的诊断和治疗。此外,癌症微生物组最近得到了重新定义。肿瘤内微生物和癌症相关循环微生物DNA(cmDNA)的鉴定推动了癌症微生物组领域的新研究。在这篇综述中,我们从全新的角度定义了人类共生微生物系统和癌症微生物组,并强调cmDNA作为癌症液体活检中有前景的生物标志物的潜在价值。我们概述了所有关于cmDNA与癌症关系的现有研究,以及cmDNA在癌症精准医学中潜在的临床前和临床应用前景,以及在这个新兴领域中需要克服的关键问题。